Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

NCT05140694 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the medications empagliflozin and dulaglutide can help people with type 2 diabetes and fatty liver disease.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 135 people Planned (estimated).

Who can join Ages 20–90 · all sexes

Timeline Started 2023-12 · est. completion 2025-12

What this study is testing ClinicalTrials.gov NCT05140694 ↗

Description as written by the study sponsor.

The co-administration of SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on glycemic control in subjects with type 2 diabetes mellitus and MAFLD better than empagliflozin or dulaglutide alone. The SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on fatty liver disease in subjects with type 2 diabetes mellitus and MAFLD.

Treatments tested

Empagliflozin also known as Jardiance Drug

Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
Dulaglutide also known as Trulicity Drug

Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
Empagliflozin and Dulaglutide also known as Jardiance and Trulicity Drug

Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly

Main thing measured	Changes of HbA1c level
Sponsor	Seoul National University Bundang Hospital
Conditions studied	Metabolic-associated Fatty Liver Disease, Type 2 Diabetes
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05140694 ↗